Medicine recalls
|
| |
| Canada: Sanofi-Aventis Avalide Product Recall |
| |
Health Canada announces that Sanofi-Aventis Canada Inc. is recalling two irbesartan/hydrochlorothiazide containing products (i.e Avalide 300-12.5 mg Tablets; Avalide 150-12.5 mg Tablets) from retailers and healthcare practitioners due to the presence of impurity 5-(4-(azidomethyl)-[1,1-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration limit in affected lots. Details are as follows:
Avalide 300-12.5 mg Tablets (lot no. FT01644)
Avalide 150-12.5 mg Tablets (lot nos. ET02879, FT01327)
Please refer to the following website in Health Canada for details:
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../75849r-eng.php
In Hong Kong, the above products are not registered pharmaceutical products.
Ends/ Thursday, June 17, 2021
Issued at HKT 12:30
|
| |
